What Are the Different Types of Prokinetic Drugs?

Prokinetic agents are a class of medications designed to enhance gastrointestinal motility by stimulating smooth muscle contractions in the stomach and intestines. They are commonly prescribed for conditions such as gastroparesis, functional dyspepsia, gastroesophageal reflux disease (GERD), and postoperative ileus.

Several prokinetics are approved for clinical use worldwide, though availability varies by region. Metoclopramide remains one of the most widely used dopamine D₂ receptor antagonists; it accelerates gastric emptying and exerts antiemetic effects via central and peripheral mechanisms. Due to its potential to cause tardive dyskinesia—especially with prolonged use or high doses—it is typically recommended for short-term use (≤12 weeks) and at the lowest effective dose.

Domperidone, another dopamine D₂ antagonist, acts predominantly peripherally with minimal blood–brain barrier penetration, resulting in a lower risk of neurological adverse effects compared with metoclopramide. While approved in many countries—including Canada, the UK, and across Europe—it is not FDA-approved in the United States for prokinetic indications due to concerns about cardiac arrhythmias, particularly QT prolongation, especially in patients with underlying heart disease or electrolyte imbalances.

Prucalopride is a selective, high-affinity 5-HT₄ receptor agonist approved primarily for chronic idiopathic constipation. Though not indicated for upper GI motility disorders, emerging evidence supports its off-label use in certain cases of delayed gastric emptying, particularly when serotonin signaling is implicated in motility dysfunction.

Other agents include erythromycin and its derivatives—macrolide antibiotics that act as motilin receptor agonists—used experimentally or in refractory gastroparesis. However, tachyphylaxis often develops within days, limiting long-term utility. Newer investigational agents, such as velusetrag and relamorelin, target multiple motilin and ghrelin receptors and are under evaluation in clinical trials for diabetic gastroparesis and other motility disorders.

Clinical selection of a prokinetic agent depends on the underlying diagnosis, patient comorbidities (e.g., cardiac history, renal or hepatic impairment), concomitant medications, and regional regulatory approvals. Close monitoring for adverse effects—including QT interval prolongation, extrapyramidal symptoms, and drug–drug interactions—is essential for safe and effective use.